Patents Examined by Rebecca L. Anderson
  • Substituted triazoles and methods relating thereto
    Patent number: 11021449
    Abstract: Substituted 1,2,3-triazole compounds are disclosed which have utility in the treatment of a variety of neurological disorders. The compounds provided herein have the general structure: wherein R1, R2, R3 and n are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound provided herein in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for treating neurological disorders in a subject in need thereof.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: June 1, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Neil J. Ashweek, John P. Williams, Deborah Slee, Manisha Moorjani
  • Cyanopyrrolidine derivatives with activity as inhibitors of USP30
    Patent number: 11014912
    Abstract: The present invention relates to substituted-cyanopyrrolidines of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: May 25, 2021
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Martin Lee Stockley, Mark Ian Kemp, Andrew Madin, Michael David Woodrow, Alison Jones
  • Process for the preparation of alectinib
    Patent number: 11014919
    Abstract: The present invention relates to a process for preparing alectinib, or a pharmaceutically acceptable salt thereof, and to related intermediates.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: May 25, 2021
    Assignees: Fresenius Kabi IPSUM S.r.l., Alma Mater Studiorum—Università di Bologna
    Inventors: Walter Cabri, Alessandra Tolomelli, Assunta De Nisi, Lucia Ferrazzano
  • C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use
    Patent number: 11008338
    Abstract: In its many embodiments, the present invention provides certain C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, R2, R3, RA, ring A, m, n, -L1-, ring B, RB, and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: May 18, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wen-Lian Wu, Jared N. Cumming, Brandon M. Taoka, Xing Dai
  • Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
    Patent number: 10995100
    Abstract: The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X1, X2, X3, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: May 4, 2021
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Venkateshwar Rao Gummadi, Susanta Samajdar
  • Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
    Patent number: 10988454
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: April 27, 2021
    Assignees: AbbVie Overseas S.à.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Concise process for preparing 3-pyrrolidine carboxylic acid derivatives
    Patent number: 10988446
    Abstract: The present invention relates to a process for preparing 3-pyrrolidine carboxylic acid derivatives, and particularly a simple process for preparing 5-substituted 3-pyrrolidine carboxylic acid derivatives. In addition, the present invention relates to a novel pyrrolidine carboxylic acid derivative, its manufacture, pharmaceutical compositions containing it and its use as a catalyst.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: April 27, 2021
    Assignee: OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION
    Inventors: Fujie Tanaka, Feng Yin
  • Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
    Patent number: 10981890
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: April 20, 2021
    Assignees: AbbVie Overseas S.à.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Oxadiazole compound and use thereof as pesticides
    Patent number: 10980233
    Abstract: Provided is a compound having excellent control efficacies against pests. Specifically, a compound represented by formula (I) is provided: In the compound represented by formula (I), G represents a benzene ring or pyridine ring, etc.; A represents a hydrogen atom or a C1-C6 alkyl group, etc.; m represents 0, 1, 2, or 3; RX1 represents a hydrogen atom, etc.; RX2 represents a hydrogen atom, etc.; E represents a OR3, etc.; and R3 represents a hydrogen atom or a C1-C6 alkyl group, etc. The compound represented by formula (I) has excellent control efficacies against pests.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: April 20, 2021
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Hiroto Tamashima
  • Crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis
    Patent number: 10968192
    Abstract: Methods of preparing, and solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide, and salts, solvates and cocrystals thereof, are disclosed.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: April 6, 2021
    Assignee: Lexicon Pharmaceuticals, Inc.
    Inventors: Mark Stephen Bednarz, Kuangchu Dai, Jeffrey Manning Eckert, Ngiap-Kie Lim, Lauren Sirois, Wenxue Wu, Matthew Mangzhu Zhao
  • Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors
    Patent number: 10968223
    Abstract: A process for the preparation of a compound of formula (Ia) or a pharmaceutically acceptable salt, or N-oxide thereof that includes reacting a compound of formula (IIIa) or (Va) with a compound of formula (IX) to form the compound of formula (Ia)
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: April 6, 2021
    Assignee: Proximagen, LLC
    Inventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory
  • Tricyclic sulfones as RORmodulators
    Patent number: 10968177
    Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: April 6, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Douglas G. Batt, T. G. Murali Dhar
  • Inhibiting agents for Bruton's tyrosine kinase
    Patent number: 10961237
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: March 30, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Joseph P. Lyssikatos, Fengmei Zheng, Matthew Peterson, Daniel B. Patience
  • Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
    Patent number: 10954259
    Abstract: This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: March 23, 2021
    Assignee: COMPASS PATHFINDER LIMITED
    Inventors: Derek John Londesbrough, Christopher Brown, Julian Scott Northen, Gillian Moore, Hemant Kashinath Patil, David E. Nichols
  • Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
    Patent number: 10947257
    Abstract: This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: March 16, 2021
    Assignee: COMPASS PATHFINDER LIMITED
    Inventors: Derek John Londesbrough, Christopher Brown, Julian Scott Northen, Gillian Moore, Hemant Kashinath Patil, David E. Nichols
  • Compounds
    Patent number: 10946025
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: March 16, 2021
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr
  • Compounds
    Patent number: 10934278
    Abstract: The present invention provides compounds of the formula (I) and their use as Kv3 modulators.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: March 2, 2021
    Assignee: Autifony Therapeutics Limited
    Inventors: Giuseppe Alvaro, Agostino Marasco, Guido Marconi
  • Nitrogen and dioxolane-containing hydrofluoroethers and methods of using the same
    Patent number: 10934281
    Abstract: Described herein is dioxolane-containing compound of formula (I) wherein (i) Rf1 and Rf2 are independently linear or branched perfluoroalkyi groups having with 1-8 carbon atoms and optionally comprise at least one catenated heteroatom, or (ii) Rf1 and Rf2 are bonded together to form a ring structure having 4-6 carbon atoms and optionally comprise one or more catenated heteroatoms; Rf2 is a linear or branched perfluoroalkyi groups having with 1-3 carbon atoms; and R4 and R5 are independently selected from H, F, Cl, a linear or branched alkyl group having 1-3 carbon atoms, optionally wherein the alkyl group comprises at least one of: fluorine, chlorine, a hydroxyl group, or a catenated heteroatom; for use in cleaning compositions, as an electrolyte solvent, as a heat transfer fluid, or a vapor phase soldering fluid.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: March 2, 2021
    Assignee: 3M Innovative Properties Company
    Inventors: Georgiy Teverovskiy, Michael G. Costello, William M. Lamanna
  • Quinoline derivatives as TAM RTK inhibitors
    Patent number: 10934274
    Abstract: The present invention relates to novel compounds which are inhibitors of TAM (Axl, Mer and Tyro 3) and/or Met family receptor tyrosine kinases (RTKs). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by a receptor of the TAM family, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer, refractory cancer and cancer metastases.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: March 2, 2021
    Assignees: QURIENT CO., LTD., LEAD DISCOVERY CENTER GMBH
    Inventors: Kiyean Nam, Jaeseung Kim, Seohyun Ahn, Yeejin Jeon, Doohyung Lee, Dongsik Park, Young-In Yang, SaeYeon Lee, Jeongjun Kim, Jiye Ahn, Hana Kim, Chun-won Jung, Carsten Schultz-Fademrecht
  • Nuclear transport modulators and uses thereof
    Patent number: 10925859
    Abstract: Compounds of formula I: and pharmaceutically acceptable salts, solvates, or hydrates thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts, solvates, or hydrates and the compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: February 23, 2021
    Assignee: Biogen MA Inc.
    Inventors: Vincent P. Sandanayaka, Sharon Shechter, Sharon Shacham, Dilara McCauley, Erkan Baloglu